. Moreover, the highest inhibitory activity on plasma PGE2 level was displayed also with 6h, 61 and 5g (71, 70,68.5% respectively, 0.lmmolkg b.wt.) compared with indomethacin (60%, 0.01 mmolkg b.wt.) as a reference drug. In addition 6i, 6k, 6p, 6r, 6t and 6v were devoid of any ulcerogenicity.
Introduction
Many nonsteroidal antiinflammatories (NSAIDs) are now widely used in the treatment of inflammatory disorders. However , despite their wide spread use , none of the presently available agents are ideal , each has its shortcoming [I] . The need for more effective and safer agents for treating inflammatory conditions is reflected in the growing list of new compounds undergoing clinical trials.The fenamates represent a class of NSAIDs that share as their common structural feature an N-arylanthranilic acid [2] . Their mechanism of action is inhibtion of cyclooxygenase (COX) activity and thereby the production of prostaglandins [3] . The fenamates are differentiated by their aryl substituents as shown by meclofenamic acid (la) [4] , mefenamic acid (lb) [5] and flufenamic acid (lc) [6] . The most active derivatives have substituents at positions 2 , 3 and 6 of the ring attached to the anthranilic acid nitrogen atom . Also, the pyridyl moiety of clonixin (2a) [7] and niflumic acid (2b) [8] can be considered isosteric to the aryl one of fenamic acid derivatives.
la: X=2,6-C12, 2a: X=2-CH3, 3-C1 (Clonixin) lb: X= 2,3-(CH3)2 (Mefenamic acid) 2b:X= 3-CF3 (Niflumic acid) lc: Despite the significant potency exhibited by these fenamates, they display various side effects as gastrointestinal disturbances, ulcerogenicity [9] and renal toxicity [lo] . Thus, among the attempts to achieve safer agents is the esterification of the carboxylic function. This is well represented by glaphenine (3a) [l 11 and floctaphenine (3b) [l 11, in which the N-aryl ring of fenamic acid is replaced by the substituted heterocylic quinolinyl moiety. 3a : X= 7-C1 (Glaphenine); 3b : X= 8-CF3 (Floctaphenine Further development in this area is extended through search for other active heterocylic biological isosteres of N-arylanthranilic acid. Thus, the replacement of the carboxylic acid hnctionality of several fenamates with acidic heterocyles e.g. 1,3,4-oxadiazole-2-thione 4 provided dual inhibitor of cylooxygenase and 5-lipooxygenase enzymes [12] .
I
Het 5a -g (Table I ), 6a-v (Table 2) X = 0 or S RI,R2 = H, Cl, CH3, OCH3 Het = 4-pyridyl (5a-g), 4-quinolinyl(6a-v) All these premises focused the intense interest for the search of novel analgesic and antiinflammatory agents that belong to the class of fenamates having the general framework 5 and 6 in order to modulate the biologic effects and abolish others.
The synthesis and pharmacological screening of the analgesic, antiinflammatory activities, as well as the ulcerogenic effect of series of: a): 5-[2-(4-pyridyl) 5a-g (c.f. Table 1) 6a-v (c.f. 
The mass spectra were run on Finnigan Mat SSQ-7000 spectrometer, 70 eV. Elemental analyses were determined in the Microanalytical Centre, Cairo University,.
The methyl anthranilates 9b-d [13] (Scheme l), were obtained according to the procedure cited in ref. [12] . A methanolic solution of the corresponding anthranilic acid derivative was refluxed for 14 h with thionyl chloride.
2-Aminobenzoic acid hydrazides 8a-d [14] (Scheme 1).
To 0.032 mol of each of the methyl anthranilate esters 9a-d was added llml (0.07 mol) of 80% hydrazine hydrate. The reaction mixture was refluxed overnight. After cooling, the required hydrazides 8a-d were precipitated and purified by crystallization fiom 2-propanol. 8d: m.p.129 "C, yield 95%, elemental analysis, calcd. for C9H13N303; C: 51.18; H: 6.20; N: 19.90 . Found: C: 5 1.35; H: 6.41; N: 19.97 .
General procedure for synthesis of 5-(2-aminoary1)-1,3,4-oxadiazol-2(3H)-ones 7a-d [14] . Method A (Scheme 1)
A solution of 0.01 mol of each ofthe 2-aminobenzoic acid hydrazides 8a-d in 30 ml of tetrahydrofuran, was heated under stirring to 40-50 "C, followed by portionwise addition of 1.78 g (0.01 1 mol) of carbonyldiimidazole during 15 min. Then, the reaction mixture was refluxed for 14h. Most of the organic solvent was distilled under reduced pressure, then water was added to precipitate 7a-d, which were filtered and purified by crystallization fiom 2-propanol: water.7d:m.p.263 "C, yield 62%, elemental analysis, calcd. for CI0HllN3O4: C: 50.63; H: 4.76; N: 17.71. Found: C: 50.76; H: 4.92; N: 17.54 .
General procedure for the synthesis of 5-(2-Aminoaryl)-1,3,4-oxadiazole-2(3I-3)-thiones 7e-g [15] . A mixture of 0.01 mol of the appropriate 2-(4-pyridyl) amino benzoic acid methyl ester lla,c,d and hydrazine hydrate (80%, 10 ml, 0.07 mol) was heated to reflux overnight.
After cooling, the appropriate hydrazide 12a,c,d was precipitated, filtered and crystallized from 2-propanol (c.f. Pharmacology:
1.Analgesic activity:
The analgesic effect of the prepared compounds 5a-g and 6a-v was investigated using 
2.Antiinflammatory activity:
The inhibitory activity of the tested compounds on carrageenan-induced rat's paw edema were determined according to the method of Winter et a1 [18] . Groups of adult male albino rats (120-160 g) of 6 animals each were fasted for 18 h before beingorally dosed with the tested compounds5a-gand6a-vin a dose of 0.1 mmollkg b.wt.
[l9] (as aqueous suspension in 7% tween 80) one hour before carrageenan challenge. Foot paw edema was induced by subplanter injection of 0.05ml of 1% suspension of carrageenan in saline into the plantartissue of one hind paw. An equal volume ofsaline was injected into the other hind paw andserved as control. Four hours after compound administration, the animals were decapitated, blood samples were collected and the paws were rapidly excised. The average weight ofedema was estimated for the treated as well as the control groups and the percentage inhibition of weight of edema was also evaluated [20] . Mefenamic acid (0.2 mmollkg b.wt.) [21] was employed as standard against which the tested compounds were compared.
3.Estimation of Plasma Prostaglandin E2 (PGE 2):
Plasma was separated from heparinized blood collected from rats ( n=6) by centrifkgation at 12000g for 2 minutes at 4°C and immediately stored frozen at -20°C until assayed. The Assay Designs'Correlate-EIA Prostaglandin E2 (PGE2) Kit is a competitive immunoassay for the quantitative determination of PGE2 in biological fluids [22] . The kit uses a monoclonal antibody to PGE2 to bind, in a competitive manner, the PGE2 in the sample. After simultaneous incubation at room temperature, the excess reagent was washed away and substrate was added. After a short incubation time, the enzyme reaction was stopped and the yellow colour generated was read on a microplate reader (DYNATECH, MR 5000) at 405 nrn. The intensity of the bound yellow colour is inversely proportional to the concentration of PGE2 in either standards or samples.
4-Ulcerogenic effect in rats:
Groups of adult male albino rats of six animals each (120-160 g), were fasted overnight, then orally given the tested compounds (0.1 mmolkg b.wt.).Four hours later, animals were killed, their stomachs were removed, opened along the greater curvature, and the number of ulcers were assessed by adopting the method of Core11 et al [23] .The results were compared with that of mefenamic acid (0.2 mmol/kg b.wt.) as reference drug.
Statistical a n d d a t a analysis:
Data are expressed as means k s.e.m. Statistical comparison between different groups was done using one way analysis of variance (ANOVA), followed by multiple comparison test (post hoc LSD). Significance was accepted at p <0.05.
Results a n d Discussion
Synthesis:
In Scheme 1, the methyl anthranilate esters 9a-d were prepared from their corresponding anthranilic acid derivatives 10a-d by treating with SOC12 in methanol [13] , which were converted to the corresponding hydrazides 8a-d [14] by heating with hydrazine hydrate in methanol. (Table 1 ) and 6a-v (Table 2) were achieved by refluxing either 4-bromopyridine hydrochloride or 4-chloroquinoline derivatives with 7a-g in an ethanolic solution, respectively; while catalytic amount of HCl was added in case of 6a-v (Schemel). Several trials failed to convert the N-(7-chloroquinoline) anthranilic acid hydrazide (14) to the target compounds 6a or 6s via Methods A or B, respectively, (Scheme 2), due to the difficulty of solubility of 14 in various solvents. On the other hand, the desired 2-(4-pyridyl) aminophenyl-1,3,4-oxadiazol-2(3H)-ones 5a and thiones 5c-g were achieved in good yields (Scheme 2 , (Tables 4 and 5) showed the NH signal of 1,3,4-oxadiazol-2(3H)-ones and 2(3H)-thiones at 6 12.00-12.80 and 6 14.25-14.55 ppm, respectively (and were exchangeable with D20). The mass spectra of 5 and 6 revealed compatible molecular ion peaks (Tables 4 and 5 ).
2.Pharmacology:

Analgesic activity
The data presented in Table 6 revealed the analgesic activity of both the pyridyl 5a-g and quinolinyl 6 a-v series. Compound 2-(4-pyridyl) aminophenyl-oxadiazol-2(3H)-one (5a) was the most active one in the pyridyl series 5a-g ( Fig. 1) . The analgesic activity of the pyridyl oxadiazol-2-ones 5a-d was arranged in the following decreasing order :5a>5b>5d, while compound 5c lacked the analgesic activity. Concerning the pyridyl oxadiazole-2-thiones 5e-g, the 5-methylphenyl substituent 5f displayed the highest analgesic activity. The analgesic potential was arranged in the following decreasing order: 5f >5g >5e. Regarding the analgesic activity of the quinolinyl oxadiazol-2-ones 6a-r, it was found that compound 6i was the most active one, where both the phenyl and quinolinyl rings are substituted with 5-Cl and 7-CF3, respectively. Meanwhile, compounds 6k and 60
were devoid of any activity. The analgesic effect of the different congeners of this group was arranged in the following decreasing order: 6i> 6q> 6p> 6e=6c> 6r=6d> 6a =61=6n> 6m=6f> 6h> 6b> 6j. Concerning the quinolinyl oxadiazole -2-thiones 6 s-v, compound 8 -trifluoromethyl-quinolinyl oxadiazole-2-thione 6v was the most active one. The analgesic activity of the other congeners was arranged in the following order: 6v>6s>6u>6t.
Conclusively, analgesic activity was augmented by the pyridyl oxadiazol-2-one and 2-thione moieties, in addition to the trifluoromethyl quinolinyl one as achieved with compounds 5a > 5f >6i >6v, respectively at a dose level of 0.6 and 0.7 mmolkg b.wt. , 30 to 45 min from compound administration. Their analgesic activities were higher than that of mefenamic acid (0.4 mmoVkg b.wt.) used as reference drug.
Antiinflammatory activity
The evaluation of the antiinflammatory activity of the pyridyl5a-g and quinolinyl6a-v series was illustrated in Table 7 Regarding the pyridyl oxadiazole-2-thiones 5e-g, the 4,5-dimethoxy substituent of the phenyl moiety in 5g augmented the inhibitory activity (84%, 0.1 mmolkg b.wt.) compared with mefenamic acid. The other congeners showed decrease in the antiinflammatory activity in the following order: 5g > 5f >5e. On the other hand, in the quinolinyl oxadiazol-2-ones 6a-r, both the 5-chloro phenyl and the 7-chloro, 3-ethoxycarbonyl quinolinyl moieties of 6h potentiated the inhibitory effect (93%, 0.1 mmol/kg b.wt.) compared with mefenamic acid value. Moreover, compounds 6a-r significantly decreased the edema of the rat's paw in the following order: 6h >61>6d >60 >6b >6f >6e >6i >6a >6p >6k >6r >6n >6m >6g >6c >6j >6q. Concerning the quinolinyl oxadiazole-2-thiones 6s-v, compound 6t was the most effective analogue, where the quinolinyl moiety is substituted with ethoxycarbonyl and chloro groups in the 3 and 7 positions, respectively. It exhibited inhibitory activity (67%, 0.1 mmoVkg b.wt.) superior to mefenamic acid value as reference drug .The antiinflammatory activity was arranged in the following decreasing order : 6t > 6s > 6u > 6v. Conclusively, the highest antiinflammatory activity was achieved with compounds 6h, 61, 5g, 6d (93, 88, 84 and 81%), respectively (c.f. fig. 2 ) using mefenamic acid as reference standard.
Plasma prostaglandin E2 (PGE2) level
The data presented in Table 8 level in this group was arranged in the following decreasing order: 6t>6s>6u>6v. In general, the highest inhibitory effect on plasma PGE2 level was achieved with compounds 6h>61>5g (0.1 mmollkg b.wt.) in the previous decreasing order ( Fig. 3 ).
Ulcerogenic effect
The data presented in Table 7 showed the ulcerogenic effect of the pyridyl 5a-g and the quinolinyl 6a-v series compared with mefenamic acid as reference drug. In the pyridyl oxadiazol-2-ones 5a-d, compound 5-[4,5-dimethoxy -2-(pyridin-4-y1amino)-phenyll-3H- [1, 3, 4] oxadiazol-2-one (5d) exhibited the highest ulcerogenic effect. Moreover, 5a and 5c both had similar ulcerogenicity. Their ulcerogenic effect was arranged in the following decreasing order: 5d>5a=5c>5b. Concerning the pyridyl oxadiazole-2-thiones Se-g, compound
5-[4,5-dimethoxy-2-(pyridin-4-ylamino)-phenyl]-3H-[l,3,4]-oxadiazole-2-thione
(5g) possessed the highest ulcerogenicity .The different congeners showed a decrease in the ulcerogenic effect in the following order : 5g > 5f >5e. Regarding the quinolinyl oxadiazol-
2-ones 6a-r, compound 5-[2-(7-trifluoromethyl-quinolin-4-ylamino)-phenyl]-3H-[l,3,4]-
oxadiazol-2-one (6d) exhibited the highest ulcerogenic effect. Furthermore, compounds 61 and 6n both had similar effects. Also compounds 6e, 6f, 6g and 60 possessed the same ulcerogenicity, as well as, 6b, 6j, 6m and 6q exhibited similar effects. On the other hand, compounds 6i, 6k, 6p and 6r were devoid of any ulcerogenic effect. The different congeners of this series showed a decrease in the ulcerogenic effect in the following decreasing order: 6d>6a>61=6n>6h>6e= 6f=6g=60>6b=6j=6m=6q=6~>6i=6k=6~=6r. In the quinolinyl oxadiazole-2-thiones 6s-v, the 5-[2-(7-chloro-quinolin-4-y1amino)-phenyll-3H-[1,3,4]-oxadiazole-2-thione (6s) exhibited the highest ulcerogenic effect. On the otherhand, 6t and 6v were devoid of any ulcerogenic effect .The ulcerogenicity was arranged in the following decreasing order: 6s>6u>6t=6v. Conclusively, compounds 6i, 6k, 6p, 6r, 6t and 6v were devoid of any ulcerogenicity, while mefenamic acid, (as reference drug) exhibited an ulcerogenic effect superior to that of the tested compounds.
In conclusion, the highest analgesic activity was achieved with the pyridyl oxadiazol-2-one 5a (0.5, 0.6 and 0.7 mmol /Kg b.wt.). Also, the replacement of both the N-phenyl and carboxylic acid fbnctions of mefenarnic acid, with either substituted quinolinyl and oxadiazol-2-one moieties as represented with 6h and 61 or with pyridyl and oxadiazole-2-thione such as 5g, augments the antiinflammatory activity compared with mefenamic acid as reference drug. Regarding the ulcerogenic effect of 5a, 6h and 61, it was much less than that of mefenarnic acid, while the same effect was observed with 5g. Since the mechanism of action of the fenamates is inhibtion of cyclooxygenase (COX) activity and thereby the production of prostaglandins [3] and since carrageenan in the paw edema model, increases COX-2 and PGE2 level [1, 24] and inflammation could be blocked by a selective COX-2 inhibitor [25, we can deduce fi-om the present results that the most potent compounds under investigation may act through inhibition of COX-2. 
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